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Background: Ibrutinib is a Bruton’s tyrosine-kinase (BTK) inhibitor that is approved as a
second-line treatment in chronic lymphocytic leukemia (CLL). While recent trials have
demonstrated impressive results for ibrutinib, there remains a paucity of real-world data on
its use in the clinical setting.
Methods: In this single-center study carried out at Brighton and Sussex University
Hospitals, we retrospectively compared outcomes in 38 patients with relapsed CLL who
received ibrutinib versus those who received conventional ﬁrst- and second-line therapies.
Results: Our results demonstrate improved progression-free survival (PFS, p=0.022) with
ibrutinib versus conventional second-line therapies and survival comparable to conventional
ﬁrst-line therapies. However, there was a high frequency (81.6%) of adverse events asso-
ciated with ibrutinib therapy, including 2 cases of death secondary to sepsis and a further 7
cases of discontinuation of treatment due to adverse events. We also identify del13q14.3 as
an adverse predictor of response to ibrutinib with respect to both overall survival (p=0.014)
and PFS (p=0.008), suggesting that these patients may be better suited to receiving the BCL2
inhibitor venetoclax.
Conclusion: Whilst there is robust evidence for improved outcomes with ibrutinib, we ﬁnd
that survival in patients with del13q14.3 is reduced and that the rate of adverse events and
discontinuation in clinical practice is higher than anticipated from clinical trials.
Keywords: CLL, chronic lymphocytic leukaemia, relapsed, real-world, ibrutinib, adverse
events
Introduction
At present, conventional ﬁrst-line treatment for chronic lymphocytic leukemia (CLL)
in the UK is intermittent chemotherapy or chemo-immunotherapy delivered intrave-
nously in the hospital setting; and until recently, the treatment for the relapsed disease
was much the same.
The landmark success of imatinib, a targeted oral chemotherapy agent producing
impressive and durable remissions in chronic myeloid leukemia,1–3 heralded research
into the development of similar agents in CLL. Increased understanding of the central
role of Bruton’s tyrosine kinase (BTK) in B-cell function led to the development of
ibrutinib,4,5 a small molecule producing targeted inhibition of BTK, which has been
shown to effectively impair B-cell receptor signaling and cellular proliferation.6,7
In clinical trials, ibrutinib has since been shown to be highly efﬁcacious in
relapsed or refractory CLL, with progression-free survival (PFS) rates reported at
Correspondence: Timothy Chevassut
Department of Haematology, Royal
Sussex County Hospital, Brighton and
Sussex University Hospitals NHS Trust,
Eastern Road, Brighton BN2 5BE, UK
Tel +44 127 387 3232
Email T.chevassut@bsms.ac.uk
Journal of Blood Medicine Dovepress
open access to scientiﬁc and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Journal of Blood Medicine 2019:10 199–208 199
DovePress © 2019 Nuttall et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/JBM.S202286
 
Jo
ur
na
l o
f B
lo
od
 M
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
18
4.
67
.7
4 
on
 1
6-
Ju
l-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
96% at 30 months in the RESONATE trial.8 Consequently,
ibrutinib became the ﬁrst oral chemotherapeutic agent to
be approved in the UK by NICE for the treatment of
relapsed CLL or CLL with high-risk cytogenetics.
Furthermore, with increasing evidence of the efﬁcacy of
ibrutinib as a ﬁrst-line treatment and in combination with
other agents,9–11 its use in clinical practice may soon
become more widespread. Clinical trials are ongoing to
evaluate its efﬁcacy in this context.
There is also increasing research into prognostic fac-
tors inﬂuencing response to ibrutinib treatment. When
compared with alternative chemotherapy agents, the evi-
dence from clinical trials suggests that ibrutinib improves
the response rate in patients with a 17p deletion or TP53
mutation,8,12,13 making it a valuable option now approved
as ﬁrst-line treatment in patients with this high-risk cyto-
genetic abnormality. However, the signiﬁcance of other
genetic abnormalities in predicting response to treatment
is yet to be established.
Most notably, despite 3 years of routine use in the UK,
data reﬂecting real-world experience and long-term fol-
low-up with ibrutinib in the clinical setting are lacking.
Of particular interest to patients, there remains only lim-
ited information available outside of the context of clinical
trials, on the adverse event proﬁle of the drug and the
likelihood of a disruption in or discontinuation of therapy.
Research suggests that disruption to continuous therapy, as
is often required when managing adverse effects of treat-
ment, is more frequent than was anticipated from the trial
data and is likely to have a detrimental impact on the rate
of disease progression.14,15
Consequently, in this single-center retrospective study,
we report on the clinical experience of ibrutinib therapy,
focusing on the outcomes from ibrutinib as compared to
conventional ﬁrst- and second-line treatment as well as the
adverse event proﬁle and rates of transformation to high-
grade lymphoma. We also identify prognostic markers,
which, if validated in other studies, may be used to direct
individualized patient management with respect to ibruti-
nib therapy.
Methods
This research was conducted at the Royal Sussex County
Hospital, Brighton, and Sussex University Hospital NHS
Trust, a provider of secondary level care for patients with
hematological disorders. The study conformed to the NHS
Health Research Authority criteria for not requiring
Research Ethics Committee approval (http://www.hra-deci
siontools.org.uk/ethics/index.html). It was approved by the
Individual Research Project Review Committee of
Brighton and Sussex Medical School and deemed not to
require patient consent as all patient data was anonymized.
It was conducted with complete conﬁdentiality of patient
information and with full compliance with the Declaration
of Helsinki.
One hundred and twenty patients were identiﬁed via
pharmacy chemotherapy records to be included in the
study. Electronic patient records were utilized for retro-
spective data collection of patient outcomes and adverse
events. TP53 mutational status, as well as ﬂuorescence in
situ hybridization (FISH) data for cytogenetic abnormal-
ities, was obtained where available. Very few patients were
screened for mutation of IGH; therefore, this data was not
included in any analyses.
Primary outcome measures were overall survival (OS)
and PFS. Time to disease progression was deﬁned as the
time to ﬁrst evidence of progressive disease, identiﬁed in
most cases according to the criteria published by the
International Workshop on CLL,16 or if these data were
not available, the time to starting subsequent therapy.
Since interval bone marrow assessment and regular com-
prehensive imaging is not routine clinical practice, the
accurate reporting of remission status was not possible
and consequently is not included in the analysis. The
Kaplan–Meier survival method and log-rank tests were
used for OS and PFS analyses. Statistical analysis of
survival data was performed in RStudio Version 1.1.383.
Results
In our patient population, 38 patients received ibrutinib ther-
apy between 2013 and 2017, of which 25were male (65.8%).
All patients had a documented reason for starting treatment
with ibrutinib. Reasons for starting treatment included pro-
gressive nodal disease on CT, splenomegaly, lymphocyte
doubling time less than 6 months, B-symptoms, progressive
cytopaenias or extensive bone marrow inﬁltration. All
patients receiving ibrutinib had received at least one course
of chemotherapy prior to starting ibrutinib, median 2 (1–5).
Median blood results prior to starting therapy were hemoglo-
bin 109 (68–133), platelets 107 (22–221) and lymphocytes
63.6 (0.6–260). Eighteen of 38 patients had an LDH above
laboratory reference range prior to starting ibrutinib therapy,
median 453 (199–1175). Median length of follow-up for
ibrutinib was 23 months (4–56).
The conventional treatment cohorts comprise of 82
patients receiving ﬁrst-line therapy between 2008 and
Nuttall et al Dovepress
submit your manuscript | www.dovepress.com
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2017 and 25 patients who went on to receive second-line
therapy between 2011 and 2016. Conventional treatment
groups typically received two or more agents in combina-
tion, most commonly rituximab with ﬂudarabine/cyclo-
phosphamide, bendamustine or chlorambucil, selected
according to the patient proﬁle. Other agents included
idelalesib in 2 patients and alemtuzumab in 1 patient.
The patient demographics across all groups were com-
parable with respect to age and gender (Table 1). The
median time from diagnosis to initiating treatment was
22 (0–293), 50.5 months (7–205) and 81 months (13–
310) in ﬁrst-line treatment, second-line treatment and ibru-
tinib cohort, respectively.
FISH data or TP53 mutational status were available for
58/82 patients in the ﬁrst-line therapies cohort, 17/25
patients in the conventional second-line therapies cohort
and 29/38 patients in the ibrutinib cohort. 17p deletions or
TP53 mutations were reported in and 6/58 (10.3%), 3/17
(17.6%) and 9/29 patients (31.0%), respectively.
Del13q14.3 was the most frequently occurring genetic
aberration, with frequencies of 18/58 (31.0%), 5/17
(29.4%) and 9/29 (31.0%) in each group. The types and
frequency of mutations detected within the different treat-
ment groups are shown in Table 2.
In this patient population, comparing ibrutinib with con-
ventional second-line therapies revealed a marked trend
towards improved OS with ibrutinib therapy, with median
OS not reached versus median of 1,097 days (p=0.12) for
patients on conventional second-line therapies (Figure 1A).
PFSwas signiﬁcantly improvedwith ibrutinib therapy,median
not reached versus median of 593 days for conventional thera-
pies (p=0.022) (Figure 1B). Correspondingly, at 1 year after
starting treatment, 88.9% of patients receiving ibrutinib were
alive and free from progressive disease, compared to 70.8% in
patients receiving conventional second-line therapies.
In light of the improved outcomes for patients on
ibrutinib when compared with conventional second-line
therapies, we sought to compare outcomes also with ﬁrst-
line therapies. We ﬁnd that ibrutinib treatment yields com-
parable PFS and OS to ﬁrst-line treatments, with median
OS of 2,333 days with ﬁrst-line therapy, versus median not
reached with ibrutinib (Figure 1C). PFS with ﬁrst-line
therapy was 1,462 days, versus median not reached with
ibrutinib (Figure 1D).
Notably, when patients receiving ﬁrst-line therapy are
stratiﬁed according to the type of chemotherapy received,
there is a signiﬁcant difference in both OS (p=0.002) and
PFS (p=0.007) between ibrutinib, FCR and chlorambucil
monotherapy, with patients receiving FCR having the best
outcomes (Figure 2).
In the ibrutinib group, patient factors including age >70,
gender, number of prior lines of therapy and number of
cytogenetic mutations were not found to correlate with the
outcome from treatment. Similarly, when considered
together, 17p deletion and/or TP53 mutation status did not
impact signiﬁcantly on either OS or PFS with ibrutinib
Table 1 Patient demographics and outcomes from treatment
Conventional ﬁrst-line
therapy
Conventional second-line
therapy
Ibrutinib
Number of patients 82 25 38
Male gender (%) 48/82 (58.5%) 16/25 (64.0%) 25/38 (65.8%)
Median age at diagnosis (range) 69 (38–91) 70 (42–83) 64 (47–80)
Median age at time of treatment (range) 72.5 (40–94) 75 (44–87) 72 (53–87)
Median number of previous therapies (range) 0 (0–0) 1 (1–1) 2 (1–5)
Median months from diagnosis to starting treat-
ment (range)
22 (0–293) 50.5 (7–205) 81 (13–310)
Median number of genetic aberrations (range) 0 (0–3) 1 (0–3) 1 (0–7)
Median OS 2,333 days 1,097 days Not reached
OS at 1 year (95% CI) 85.1% (77–93) 96.0% (89–100) 100% (100–100)
OS at 3 years (95% CI) 76.2% (67–87) 50.8% (32–81) 71.5% (48–100)
Median PFS 1,462 days 593 days Not reached
PFS at 1 year (95% CI) 77.1% (68–87) 70.8% (55–92) 88.9% (79–100)
PFS at 3 years (95% CI) 57.4% (47–71) 31.8% (16–65) 69.8% (56–88)
Abbreviations: OS, overall survival; PFS, progression-free survival.
Dovepress Nuttall et al
Journal of Blood Medicine 2019:10 submit your manuscript | www.dovepress.com
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(Figure 3A). Interestingly, del13q14.3 was found to corre-
late with reduced OS (p=0.014) and reduced PFS (p=0.008)
(Figure 3B).
Adverse events were common in the ibrutinib arm and
affected 31 out of 38 patients (81.6%) (Table 3). Those
with the highest incidence were bruising or bleeding pro-
blems (15 patients) and gastrointestinal disturbance (14
patients). Recurrent or severe infections and neutropenia
were also reported with a relatively high frequency,
affecting 7/38 and 6/38 patients, respectively. Amongst
these were two cases of severe sepsis that resulted in
death.
Overall, ibrutinib was stopped for a minimum of 1
week in 21/38 patients due to an adverse event or in
order to prophylactically minimize bleeding risk for an
invasive procedure. Therapy was discontinued completely
in 9/38 patients due to serious adverse events, most nota-
bly, cardiac rhythm abnormalities in 3 cases. Seven of
Table 2 Frequency of genetic aberrations by treatment cohort
Frequency in conventional ﬁrst-line
therapy group
Frequency in conventional second-
line therapy group
Frequency in ibru-
tinib group
Del17p or TP53
mutation
6/58 (10.3%) 3/17 (17.6%) 9/29 (31.0%)
Del13q14.3 18/58 (31.0%) 5/17 (29.4%) 9/29 (31.0%)
Trisomy 12 16/58 (27.6%) 6/17 (35.3%) 4/29 (13.8%)
Del ATM locus 6/58 (10.3%) 1/17 (5.9%) 5/29 (17.2%)
Del IGH locus 7/58 (12.1%) 3/17 (17.6%) 1/29 (3.4%)
Other 3/58 (5.2%) 3/17 (17.6%) 3/29 (10.3%)
Normal 16/58 (27.6%) 1/17 (5.9%) 4/29 (13.7%)
Overall survival in CLL with conventional second-line therapy vs ibrutinib
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Progression-free survival in CLL with conventional second-line therapy vs ibrutinib
Overall survival in CLL with conventional first-line therapy vs ibrutinib Progression-free survival in CLL with conventional first-line therapy vs ibrutinib
Figure 1 (A) Overall survival with ibrutinib versus conventional second-line therapy; (B) progression-free survival with ibrutinib versus conventional second-line therapy;
(C) overall survival with ibrutinib versus conventional ﬁrst-line therapy; (D) progression-free survival with ibrutinib versus conventional ﬁrst-line therapy.
Nuttall et al Dovepress
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these 9 patients were still alive at the time of follow-up
and 4 of these had developed progressive disease.
From our cohort of 38 patients receiving ibrutinib, 4
discontinued ibrutinib therapy due to the development of
Richter’s transformation, with 2 cases of DLBCL and 2
Hodgkin’s lymphoma. Other reasons for cessation of ther-
apy were progressive CLL in one case and development of
advanced metastatic pancreatic adenocarcinoma in one
case.
Discussion
The approval of ibrutinib therapy in 2014 has prompted a
dramatic shift in the clinical management of patients with
relapsed or high-risk CLL, away from further courses of
intravenous chemotherapy toward oral chemotherapy,
allowing patients to manage their treatment at home.
This is an appealing prospect for both patients and doctors,
but critically, the success of this novel treatment in
practice is dependent on its ability to produce favorable
clinical outcomes with an associated acceptable level of
toxicity.
The results of this study support the data on survival
outcomes from clinical trials, demonstrating improved
PFS with ibrutinib therapy as compared to conventional
second-line therapies, with an estimated PFS at 1 year of
88.9%. The patients included in our study were similar in
terms of age, gender and cytogenetic proﬁle to those
included in the RESONATE trial, which reported 84%
PFS at 1 year.8 However, consideration should also be
given to studies of ibrutinib use in clinical practice,
which have reported lower PFS rates.15,17 For example,
the Polish Adult Leukaemia Group (PALG) study of 165
patients enrolled in a compassionate use program for ibru-
tinib reported an estimated PFS of 79.7% at 1 year.18
PALG authors suggest that the lower PFS rate may be
due to poorer performance status in their study population.
Overall survival in CLL with ibrutinib vs conventional first-line therapies
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Progression-free survival in CLL with ibrutinib vs conventional first-line therapies
Ibrutinib
Chlorambucil monotherapy
Ibrutinib
Chlorambucil monotherapy
Chlorambucil monotherapy
Ibrutinib
Chlorambucil monotherapy
Ibrutinib
A B
Figure 2 (A) Overall survival with ibrutinib versus FCR and chlorambucil monotherapy, (B) progression-free survival with ibrutinib versus FCR and chlorambucil
monotherapy. FCR, ﬂudarabine, cyclophosphamide, rituximab.
Progression-free survival with ibrutinib according to del17p and/or TP53 mutation
Normal Normal
Abnormal
Normal Normal
Abnormal
Progression-free survival with ibrutinib according to del13q14.3 status
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Figure 3 (A) Progression-free survival with ibrutinib according to del17p and/or TP53 mutation status; (B) progression-free survival with ibrutinib according to del13q14.3
status.
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The data presented here are also suggestive of improved
OS when compared with conventional second-line therapies,
with an estimated 1-year OS with ibrutinib of 100%,
although the difference was not statistically signiﬁcant. The
reason for this may be due to the heterogeneity of the type of
conventional second-line therapies included in this study,
with certain regimes having better OS than others.
Interestingly, in a recent retrospective study indirectly com-
paring the use of bendamustine and rituximab versus ibruti-
nib as second-line treatment, there was no signiﬁcant
difference in OS.19 Whereas, when directly compared with
ofatumumab, ibrutinib is associated with signiﬁcantly
improved OS.8 The 1-year OS rate with ibrutinib measured
in the ofatumumab trial and others is lower than reported
here.8,20 The reason for this discrepancy is unclear, but may
reﬂect that the patients included in this study had compara-
tively lower exposure to prior therapies than in other trials, or
perhaps represents a difference in baseline characteristics
that is unmeasured in this study.
There is emerging evidence from clinical trials that ibru-
tinib monotherapy is effective as a ﬁrst-line treatment in
patients aged ≥65 and has favorable outcomes when com-
pared with conventional chemotherapy or chemoimmu-
notherapy combinations.9,11 The use of ibrutinib
monotherapy as a ﬁrst-line treatment in a more general con-
text is still to be established. When compared retrospectively
with conventional ﬁrst-line therapies, these data suggest that
BTK inhibitor therapy produces second remissions that are
similar in their durability to ﬁrst remissions. When stratiﬁed
according to the type of ﬁrst-line therapy, however, the
results of our study demonstrate a signiﬁcant difference in
both OS and PFS between ibrutinib, FCR and chlorambucil
monotherapy, with FCR producing superior outcomes, and
chlorambucil producing comparatively poor outcomes.
These results are in keeping with the report from the
RESONATE-2 trial, which showed improved OS and PFS
with ibrutinib as compared to chlorambucil monotherapy
as ﬁrst-line management in older patients.9 The data from
prior clinical trials of FCR demonstrate the efﬁcacy of this
combination of agents as a ﬁrst-line treatment, particularly
in those with a favorable cytogenetic proﬁle, with many
patients achieving a long-term remission.21,22 These data
suggest that at present, for younger patients with low-risk
characteristics, and who are able to tolerate FCR che-
motherapy, this is the optimal approach to initial
management.
It is necessary to consider; however, that in this retro-
spective study, the ibrutinib group received their treatment
more recently than the conventional ﬁrst-line therapy
population. This is acknowledged as a potential confoun-
der, which would tend to bias toward favoring ibrutinib
therapy, for example, due to improvements in general
supportive care over time. Additionally, patients receiving
ibrutinib, chlorambucil monotherapy or FCR were not
matched for baseline characteristics, since the chemother-
apy agent was selected according to patient proﬁle, taking
in to account age and comorbidities, and in clinical prac-
tice, the toxicity associated with the FCR regime often
precludes many patients from being eligible to receive it.
Therefore, large-scale randomized clinical trials will be
essential in resolving unanswered questions with regard
to ibrutinib as ﬁrst-line treatment.
Of note, there is unpublished trial data to suggest that
perhaps a move away from ﬁrst-line FCR as standard in
younger patients with cytogenetically favorable proﬁles
may be on the horizon. Results of the ECOG-ACRIN
E1912 trial, presented at the American Society of
Haematology meeting, are the ﬁrst to demonstrate the
potential for ibrutinib in combination with rituximab as a
ﬁrst-line agent in younger patients. In their study of
patients aged ≤70, at a median follow-up of 33.4 months,
ibrutinib plus rituximab produced improved OS, PFS and
reduced toxicity when compared with standard FCR
chemotherapy.23 Additionally, the results of the phase III
FLAIR trial in the UK are eagerly anticipated, particularly
as this will address the outstanding question of the efﬁcacy
Table 3 Frequency of adverse events with ibrutinib therapy
Adverse event Frequency
GI disturbance (dyspepsia, nausea, diarrhoea) 14
Bleeding/bruising 14
Recurrent infections/sepsis 7
Neutropenia 6
Rash 5
Cardiac rhythm abnormalities 3
Arthralgia 3
Headache 3
Leg swelling 2
Brittle nails 2
Leg cramps 2
Blurred vision 2
Pneumonitis 1
Malaise 1
Oral ulceration 1
Pancolitis 1
Uveitis 1
EBV reactivation 1
Abbreviations: GI, gastrointestinal; EBV, Epstein–Barr virus.
Nuttall et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
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of ibrutinib monotherapy as ﬁrst-line in younger patients.
At present, the use of ibrutinib in this context remains
guarded.
The impact of high-risk cytogenetic abnormalities such
as 17p deletion is an area of particular clinical interest,
since these patients typically respond poorly to conven-
tional chemotherapy.24 Early clinical trial data demon-
strated encouraging responses to treatment in this patient
cohort.8,12,14 In accordance with these results, the data
presented here suggest that there is no clinically signiﬁcant
difference in either OS or PFS in patients with 17p dele-
tion or TP53 mutation treated with ibrutinib.
However, these results must be interpreted with cau-
tion, considering the modest sample size in this study.
Indeed, it is worthwhile noting that the data from longer-
term follow up of patients in clinical trials suggest that
responses are less durable in this patient cohort receiving
ibrutinib as ﬁrst-line therapy, with median PFS reduced to
26 months compared to median not reached over a median
follow-up period of 5 years.25 Additionally, the data pre-
sented by the Swedish Group demonstrated a signiﬁcantly
reduced OS and PFS over a relatively short follow-up
period of 10.2 months.17
Interestingly, in our cohort of patients receiving ibruti-
nib, an adverse effect was seen with del13q14.3, leading to
a reduction in both OS and PFS. This cytogenetic abnorm-
ality is conventionally considered to be a favorable prog-
nostic marker for disease progression,24 although its
inﬂuence on outcomes from ibrutinib treatment is not
known. Possible explanations for this ﬁnding were con-
sidered, in particular, due to the prevalence of del13q14.3
in this study population, and hence its frequent occurrence
in combination with other cytogenetic abnormalities, that
the detrimental effect of this abnormality may reﬂect the
effect of a more complex karyotype. However, other cyto-
genetic abnormalities and total number of abnormalities
did not appear to affect response to ibrutinib. Validation of
these ﬁndings in larger studies with greater power to detect
more subtle impact on the outcome for rare events will be
required.
Considering these data alongside that from clinical
trials, there is substantial evidence that ibrutinib improves
disease control and survival in the setting of relapsed and
high-risk CLL. The direction of future research is therefore
pointing toward increasing application, with potential for
use as a ﬁrst-line therapy or in combination with other
agents, with initial clinical trials in this area showing
promising results.10
Nevertheless, as with all cytotoxic agents, off-target
effects limit its utility in practice. In the RESONATE trial,
overall rate of adverse events that were grade 3 or higher
was 57% in patients receiving ibrutinib.8 Subsequent stu-
dies of ibrutinib use in practice have reported similar rates
of clinically signiﬁcant adverse events.15 However, there
are many reasons why in practice, the experienced rates of
adverse events are likely to be higher than those reported in
clinical trials and retrospective research.
Despite some evidence that over time ibrutinib therapy
is associated with improved immune function,26 the data
from clinical trials demonstrate that the risk of infection
remains a signiﬁcant risk, particularly within the ﬁrst year
of starting treatment.27 Indeed, in this cohort of 38
patients, there were 7 cases of clinically signiﬁcant infec-
tion and 2 cases of death due to severe sepsis.
Additionally, there have been multiple reports of opportu-
nistic infections occurring on ibrutinib therapy, including
invasive aspergillosis and Cryptococcus.28,29 There is cur-
rently no clear guidance on antimicrobial prophylaxis or
monitoring of patients on ibrutinib therapy, and conse-
quently, severe infections continue to pose a signiﬁcant
risk.
Of additional concern is the frequency of bleeding
problems, which has resulted in serious adverse events
and, in some cases, fatality.15 Despite the exclusion of
patients deemed to have a high bleeding risk from clinical
trials, such as those taking warfarin or a strong CYP3A4/5
inhibitor, the reported frequency of bleeding problems
remained signiﬁcant at 44%, with 1% of patients experi-
encing a major hemorrhage,8 and similar results were
reported in the Swedish experience.17 Pertinently, a sec-
ondary analysis of trial data found that the incidence of
major bleeding events in patients concomitantly receiving
other types of anticoagulation or antiplatelet agents was
still elevated at 3%, suggesting that these alternative
agents are also likely to increase risk of bleeding.30
It has therefore been proposed that bleeding risk may
be managed by avoiding co-medicating with anticoagu-
lants and antiplatelet agents and temporarily holding treat-
ment for procedures with a risk of bleeding.31 However, in
clinical practice, it is often challenging to balance up the
relative risks of bleeding and thrombotic events, and until
further research is conducted in this area, guidance on best
practice is lacking.
Furthermore, the increased rates of cardiac arrhythmias
with ibrutinib use create an unfortunate paradox in antic-
oagulant management in the context of ibrutinib-induced
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bleeding risk.32 In many cases, the complexity of this med-
ical scenario ultimately results in discontinuation of ibrutinib
therapy,33 as was seen in 3 patients in this study. If ibrutinib is
continued, an anticoagulant with lower bleeding risk may be
introduced in order to reduce the risk of a secondary throm-
botic event, although as described above, objective evidence
for the safety of this approach is lacking.
The consequence of any serious adverse events in most
cases is an initial temporary pause in treatment. In some
cases, this may lead to a permanent discontinuation or the
possibility of a trial of reintroduction of therapy at a
reduced dose. We ﬁnd that temporary pauses in treatment
of at least 7 days occur in the majority of patients, which is
in agreement with the ﬁndings of the UK CLL group,15
indicating that the rate of pauses in treatment with use in
clinical practice is likely to be greater than that reported in
trials.14 We also found that 9/38 patients discontinued
treatment permanently due to reasons other than disease
progression, a rate which is again higher than that reported
in the pooled data from 4 clinical trials of ibrutinib, which
was described in 45/308 patients.34 It is likely that this
discrepancy between real-world use and clinical trial data
is due to the careful selection of trial participants, with
exclusion of patients with comorbidities that may impact
on the ability to comply with treatment.
It is not surprising that permanent cessation of therapy
results in both development of progressive disease and
reduced survival,35 but perhaps unexpectedly, treatments
breaks of a relatively short duration have also been shown
to have a signiﬁcant impact on outcomes from treatment.-
15,36 On the other hand, there is evidence from the UK CLL
group and PALG that a dose reduction of ibrutinib does not
affect OS,15,18 which supports the use of this strategy where
possible in managing adverse events in clinical practice.
Of additional interest in this study is the relatively high
rate of Richter’s transformation of CLL to lymphoma, at
10.5%. The early clinical trials reported very low levels of
disease transformation with ibrutinib, with two cases
reported in the RESONATE trial of 195 patients and zero
in the RESONATE-2 trial, where the authors report that
the only case of high-grade Richter’s transformation to
DLBCL occurred in the group of patients receiving chlor-
ambucil monotherapy.8,9 However, the rates reported in
clinical use appear to be higher, with 9/95 reported in the
Swedish group and 18/315 biopsy-proven cases reported
in the UK CLL group studies.15,17 These results suggest
that rates of transformation are likely to be higher with
routine clinical use than anticipated from clinical trials.
Conclusion
Ibrutinib is a promising novel therapy for CLL, with
evidence for improved PFS and OS when compared with
conventional second-line therapies and comparable out-
comes to ﬁrst-line therapies. The improvement in PFS as
compared to chlorambucil as a ﬁrst-line agent raises the
possibility of ibrutinib as a ﬁrst-line agent in patients
deemed unﬁt for FCR. Responses to ibrutinib therapy
amongst patients with 17p deletions and TP53 mutations
were similar to nonmutated patients, although we ﬁnd that
del13q14.3 negatively impacts survival. Given the fact that
del13q14.3 is associated with increased expression of
BCL2 due to loss of miR15a/16a, it is tempting to spec-
ulate that these patients might respond better to the BCL2
inhibitor venetoclax than to a BTK inhibitor such as
ibrutinib.
Our real-world data also reveal a number of serious
adverse events resulting in permanent cessation of ther-
apy in 7 patients. Of further concern, 2 patients died of
sepsis and 4 patients developed Richter’s transforma-
tion. This research highlights the need for further clin-
ical trials to investigate the use of ibrutinib as a ﬁrst-line
agent in selected patient cohorts. Additionally, larger
scale studies will be required to identify and validate
prognostic markers in order to effectively predict and
monitor response to treatment. Finally, research into
mechanisms of ibrutinib toxicity and the development
of guidance on managing the risk to patients will be
crucial in reducing the frequency and severity of adverse
events.
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